Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Two-Cohort, Open-label Phase 2 Trial of the IRX-2 Regimen in Women With Squamous Cervical Intraepithelial Neoplasia 3 (CIN 3) or Vulvar Intraepithelial Neoplasia 3 (VIN 3)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03267680
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:26:37.207374+00:00
Published At
2025-04-13T00:00:00+00:00
Record Updated At
2025-04-13
Results Posted At
2025-04-13
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Cervical Squamous Cell Carcinoma In Situ", "Vulvar High Grade Squamous Intraepithelial Lesion"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-04-13"
protocolSection.identificationModule.nctId
"NCT03267680"
protocolSection.identificationModule.officialTitle
"A Two-Cohort, Open-label Phase 2 Trial of the IRX-2 Regimen in Women With Squamous Cervical Intraepithelial Neoplasia 3 (CIN 3) or Vulvar Intraepithelial Neoplasia 3 (VIN 3)"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2025-04-13"

Study condition terms

  • Cervical Squamous Cell Carcinoma In Situ (protocolSection.conditionsModule.conditions)
  • Vulvar High Grade Squamous Intraepithelial Lesion (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.